Evidence map›Paper›PMID 31970493›Full record

ArticleArchives of gynecology and obstetrics2020

The impact of p16

Lisa Gensthaler, Elmar A Joura, Laia Alemany, Reinhard Horvat, Silvia de Sanjosé, Sophie Pils

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Lisa GensthalerDepartment of Gynecology and Obstetrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Elmar A JouraDepartment of Gynecology and Obstetrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. elmar.joura@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-0885-1013
Laia AlemanyUnit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Reinhard HorvatDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Silvia de SanjoséUnit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Sophie PilsDepartment of Gynecology and Obstetrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Medical University of Vienna · ATInstitut d'Investigació Biomédica de Bellvitge · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate HPV and p16

methodsRetrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar cancer at a single tertiary care center. Histology, HPV and p16

results135 patients were included in the analysis. 32 (23.7%) showed a p16

conclusionsAge and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients with p16

Indexed as

AgedBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansMiddle AgedPrognosisRetrospective StudiesSurvival AnalysisVulvar NeoplasmsBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16HPVp16ink4aPrognosisSurvivalVulvar cancer

Identifiers

PMID31970493
PMCPMC7060959
OpenAlexW3002000986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.